title: The Three-Decade Long Journey in Heart Failure Drug Development.
abstract: Heart failure is a global disease with increasing prevalence due to an aging worldwide population with increasing co-morbidities. Despite several therapeutic options available to treat HFrEF, morbidity and mortality remain high. Importantly, no approved therapies are available to treat HFpEF. This paper will briefly summarize the burden of disease, HF classification and definitions and the landmark clinical trials in both HFrEF and HFpEF. Given the increasing incidence and prevalence of HF and the high morbidity and mortality associated with this disease, continued development efforts are essential to address the unmet needs of these patients.
authors.affiliation: Department of Cardiology, Global Medical Affairs, Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, USA. kelly.lewis@bayer.com.
authors.forename: Kelly S
authors.initials: KS
authors.lastname: Lewis
authors.affiliation: Department of Medicine, Division of Cardiovascular Medicine, Stony Brook University, Stony Brook, NY, USA.
authors.forename: Javed
authors.initials: J
authors.lastname: Butler
authors.affiliation: Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
authors.forename: Johann
authors.initials: J
authors.lastname: Bauersachs
authors.affiliation: Department of Cardiology, Global Drug Discovery, Bayer Pharma AG, Wuppertal, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Sandner
mesh_terms: D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D006333:Heart Failure / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D006801:Humans; D013318:Stroke Volume
chemical_list: D002317:Cardiovascular Agents
keywords: HFpEF; HFrEF; Heart failure; Heart failure statistics; Heart failure trials